WO2007010976A1 - Body weight gain inhibitory composition comprising d-psicose and use thereof - Google Patents

Abstract

[PROBLEMS] To inhibit the excess increase in body weight induced by various causes and to reduce the overweight. [MEANS FOR SOLVING PROBLEMS] Disclosed are: a composition comprising D-psicose for use in the inhibition of the excess increase in body weight and/or the reduction in overweight; and a composition comprising D-psicose for use in the prevention of obesity and/or the amelioration of obeseness. In the compositions, D-psicose is added in an amount of 1 to 90% by weight based on the total weight of the composition, and D-psicose means a chemical compound D-psicose and/or a derivative thereof. Also disclosed are: a method for the inhibition of the excess increase in body weight and/or the reduction in overweight in a person and/or an animal who needs the inhibition or the reduction, the method comprising administering the composition to the person or animal; and a method for the prevention of obesity and/or the amelioration of obeseness in a person or an animal who needs the prevention or the amelioration, the method comprising administering the composition to the person or animal.

Description

 Specification

 D-psicose-containing weight gain inhibitory composition and method of use thereof TECHNICAL FIELD

 [0001] The present invention relates to the use of D-psicose to suppress weight gain and / or to reduce overweight. More specifically, the present invention can suppress excessive weight gain due to various causes, reduce overweight, prevent and reduce obesity, and prevent excessive weight gain or overweight. The present invention relates to a composition, food, food material, food additive, beverage, drinking water, drug, drug substance, and feed containing D-psicose and / or a derivative thereof suitable for a person and / or animal. The present invention also relates to a method for suppressing weight gain and / or reducing overweight due to various causes.

 Background art

 [0002] Although rare sugars exist in nature, the abundance is extremely small. Rare sugars are divided into aldoses, ketoses and alcohols by chemical structure. Examples of aldoses include D-alose strength. Examples of ketoses include D-psicose strength. Examples of alcohols include aritol. However, since most of these rare sugars have been difficult to obtain because they were not mass-produced in the past, little research has been conducted on their physiological and pharmacological activities. Recently, a large-scale production method using enzymes was developed by Prof. Irimori et al., Faculty of Agriculture, Kagawa University, and some rare sugars such as D-psicose, D-allose, and aritol were produced. Research is progressing.

 [0003] From the results of previous studies, it has been clarified that rare sugars have sugars that have an effect on sugar metabolism or lipid metabolism. For example, for D-psicose, in in vitro experiments, suppression of D-Glucose transport in the isolated intestinal tract (Non-patent Document 1), promotion of insulin secretion from rat spleen j8 cell line (Patent Document 1), vascular endothelial cells Suppression of MCP-1 secretion from strains (Patent Document 1), etc., and in vivo experiments, body fat accumulation mitigating action (Non-Patent Document 2), and not becoming energy in vivo (Non-Patent Document 3), etc. However, each has been clarified.

Based on the results of previous studies, rare sugars have sugar metabolism! It has been shown that monosaccharides exist. For example, for D-psicose, in in vitro experiments, suppression of D-glucose transport in the isolated intestinal tract (Non-patent Document 1), promotion of insulin secretion from the rat spleen j8 cell line (Patent Document 1), vascular endothelial cells Suppression of MCP-1 secretion from strains (Patent Document 1), action to suppress the accumulation of neutral fat in adipocytes (Non-Patent Documents 2 and 3), etc. Reference 4), and the energy in the living body, which is not unique (Non-Patent Document 5), have been clarified.

 [0004] However, many of the effects that have been clarified in previous studies have been seen in / out of in vitro experiments, and the results of in vivo experiments were also seen in normal animals. Is. Therefore, it is still known that the effects of rare sugars in pathological animals with abnormalities in sugar metabolism or lipid metabolism such as obesity are known.

 [0005] Non-Patent Document 1: Fiscal 1999 Science and Technology Comprehensive Research Commission Regional Lead Research Research Result Report “Study on Mechanisms of Action of Rare Sugars as Pharmaceuticals” Kagawa Medical University, Masaaki Tokuda, Yoshishi Konishi, Maeda Tsuji, 2000

 Non-Patent Document 2: 2005 Japanese Biochemical Society Abstract (Kobe) “Effect of monosaccharides on fat cells” Kagawa University School of Medicine, Madoka Saito and 4 others.

 Non-Patent Document 3: 2006 International Biochemical Society Abstract (Kyoto) “Effects of Rare Sugars on the Properties of 3T3—LI Adipocytes.”

 Non-patent document 4: Fiscal 1999 Science and Technology Comprehensive Research Commission Regional Leading Research Research Results Report “Nutritional Evaluation of Rare Sugars Using Rats and Their Application to Food” Kagawa University Faculty of Agriculture, Hiroo Suzuki, Matsuo Tatsuhiro, Hashiguchi Mineo, 2000

 Non-Patent Document 5: Fiscal 2000 Science and Technology Research Fund Regional Lead Research Research Results Report “Nutritional Evaluation of Rare Sugars Using Rats and Application to Food” Kagawa University Faculty of Agriculture, Hiroo Suzuki, Matsuo Tatsuhiro, Hashiguchi Mineo, 2001

 Patent Document 1: International Publication Number W003 / 097820

 Disclosure of the invention

 Problems to be solved by the invention

[0006] There are currently 23 million people in the country who are considered obese. These people have hyperlipidemia, hyperglycemia, etc. that are simply overweight or overweight. One of the lifestyle-related diseases that often accompanies is the risk of death from diseases such as metabolic syndrome appearing in the heart, blood vessels, brain, etc., or a decline in QOL. Therefore, there is a need to prevent excessive weight gain and reduce overweight. For this purpose, it is considered that the restriction and movement of the quality and quantity of food taken daily rather than the use of pharmaceuticals are more effective for the treatment or prevention of obesity. However, dietary restrictions and exercise sometimes go too far and can harm health.

 [0007] At present, many so-called health foods that promote obesity and reduce blood lipids are also commercially available. These so-called health foods are useful as long as they are used as dietary restrictions and exercise assistance. The main ingredients of those foods currently used for the prevention of obesity include dietary fiber, low-calorie sweeteners, amino acid mixtures, etc., all of which do not taste good and have uncertain effects. There are difficulties. For this reason, the appearance of food is desired for the purpose of restricting meals and assisting exercise, and it is expected to work!

 [0008] D-psicose is a sugar with a refreshing sweetness that is about 60% stronger than sucrose, and abnormal sugar metabolism is closely related to abnormal fat metabolism, so this rare sugar has an anti-obesity effect The potential is great. Therefore, we investigated the anti-obesity effect of D-psicose using human obesity model animals.

 [0009] The purpose of the present invention based on the results of the above studies is to achieve D-psicose and / or suitable for humans and animals that are capable of suppressing overweight and reducing overweight, and that require prevention of obesity and improvement of obesity. Alternatively, the present invention provides a composition, a food, a food material, a food additive, a beverage, drinking water, a drug, a pharmaceutical raw material, a feed and the like containing the derivative. Another object of the present invention is to provide a method for suppressing an excessive increase in body weight due to various causes and reducing an overweight.

 Means for solving the problem

[0010] In the above study, the effect of D-psicose on the body weight of obese model animals was examined. As a result, the effects of suppressing the body weight gain of genetically obese animals and reducing the overweight of experimental obese animals were found. Based on the findings, the present invention has been completed through extensive research.

[0011] The present invention includes D-psicose, and suppresses excessive weight gain and / or A gist is a composition characterized by reducing overweight.

 D-psicose power is formulated to include ~ 90% by weight, and the present invention includes D-psicose and is formulated to include D-psicoseca ^ -90% by weight. The gist of the present invention is a composition characterized in that it suppresses and / or reduces overweight.

 D-psicose is D-psicose and Z or a derivative thereof, and the present invention contains D-psicose and Z or a derivative thereof, preferably formulated so that D-psicose and Z or a derivative thereof is contained in an amount of 90 to 90% by weight. The gist of the present invention is a composition characterized in that it suppresses overweight and / or reduces overweight.

 In addition, the present invention is characterized in that any of the above-described yarns and adults is used for a person and Z or an animal who need to suppress overweight and / or reduce overweight. The gist is a method of suppressing overweight and / or reducing overweight.

[0012] The gist of the present invention is a composition comprising D-psicose and characterized by preventing obesity and improving Z or obesity status.

 D-psicose strength is formulated to include 90% by weight, and the present invention includes D-psicose, which is formulated to include D-psicose ca ^ -90% by weight, to prevent obesity. And a thread and composition characterized by improving Z and obesity status.

 D-psicose is D-psicose and Z or a derivative thereof, and the present invention contains D-psicose and Z or a derivative thereof, preferably formulated so that D-psicose and Z or a derivative thereof is contained in an amount of 90 to 90% by weight. The gist of the present invention is a composition characterized by preventing obesity and improving Z or obesity status.

 The present invention also provides a method for preventing and preventing obesity, characterized by using any of the compositions described above for people and Z or animals that require prevention of obesity and improvement of Z or obesity status. Alternatively, the gist is a method for improving an obesity state.

 The invention's effect

[0013] The present invention comprises D-psicose and / or a derivative thereof as an active ingredient, and an excess of body weight. A composition having an inhibitory effect on increase and / or an effect of reducing overweight and / or a composition having an effect of preventing obesity due to various causes and / or an effect of improving obesity, and these compositions are used. It is possible to provide a method for suppressing overweight and / or reducing overweight and / or a method for preventing and / or improving obesity by various causes.

 [0014] The present invention is characterized in that it suppresses excess body weight gain and / or reduces overweight, and comprises D-psicose and / or a derivative thereof as an active ingredient, for foods, health foods, and patients. Food, food ingredients, health food ingredients, patient food ingredients, food additives, health food additives, patient food additives, beverages, health drinks, patient drinks, drinking water, health drinks, patients Drinking water, medicines, pharmaceutical ingredients, feed, livestock and / or livestock feed.

 [0015] In addition, the present invention uses a composition containing D-psicose and / or a derivative thereof to suppress overweight and / or reduce overweight and / or prevent obesity caused by various causes. Alternatively, a method for improving obesity can be provided.

 Brief Description of Drawings

 [Fig.l] Effect of repeated administration of D-Psicose on body weight of Zucker (fa / fa) rats [In the figure, *; p <0.05, * *; p <0.001 (vs distilled water administration group)〕.

 FIG. 2 shows the effect of D-Psicose on the body weight of mice administered with Aurothioglucose (ATG) [in the figure, * *; p <0.01 (vs ATG control group)].

 BEST MODE FOR CARRYING OUT THE INVENTION

[0017] With regard to D-psicose, in recent years, with the advent of epimerase (see, for example, JP-A-6-125776), for example, it has become possible to produce it from D-fructose, which is a monosaccharide abundant in nature. Although it is still expensive, it has become relatively easy to obtain. It was found that by using D-fructose as a raw material, the problem of raw material cost was solved and a hetero-oligosaccharide expected to have a new physiological activity based on D-psicose was obtained. Among monosaccharides, D-psicose is a hexasaccharide having a ketone group as a reducing group. This D-psicose is known to have D and L isomers as optical isomers. . Here, D-psicose is a known substance but rarely exists in nature, so it is defined as “rare sugar” according to the definition of the International Association of Rare Sugars.

 [0018] Rare sugars can be defined as monosaccharides (aldoses, ketoses and sugar alcohols) that rarely exist in nature. Also in the present invention, it is a rare sugar based on the above definition, and preferably ketose D-psicose. This definition is ambiguous because it is not a definition of sugar structure or properties. That is, there is no definition of an amount such as a rare sugar that is less than a certain amount. However, there are six types of aldoses that are generally abundant in nature: D-glucose, D-galactose, D-mannose, D-ribose, D-xylose, and L-arabinose. Other aldoses are defined as rare sugars. Is done. As ketose, D-fructose exists, and other ketoses are rare sugars. Other ketoses include D-tagatose, D-sorbose, L-fructose, L-psicose, L-tagatose, and L-sorbose. Sugar alcohol can be produced by reducing monosaccharides, but D-sorbitol is relatively large in nature, but the others are quantitatively small, so these are also rare sugars.

 The rare sugar D-psicose used in the present invention has been developed as a method for mass production of rare sugars from monosaccharides existing in large quantities in nature. Can be manufactured.

 [0019] The D-psicose derivative used in the present invention will be described. A compound obtained by converting the structure of a molecule from a certain starting compound by a chemical reaction is called a derivative of the starting compound. Derivatives of hexose containing D-psicose include sugar alcohols (when monosaccharides are reduced, aldehyde groups and ketone groups become alcohol groups and polyhydric alcohols of the same number as carbon atoms), uronic acid ( It is an oxidized monosaccharide alcohol group. Naturally, D-glucuronic acid, galacturonic acid, and mannuronic acid are known. Amino sugar (substituted with OH group NH2 group of sugar molecule, darcosamine, chondrosamine) , Glycosides, etc.) are common, but are not limited thereto.

[0020] Rare sugars are naturally occurring monosaccharides, albeit in trace amounts. D-psicose is considered to be less toxic to animals, with no reported toxicity to humans. D-psicose is a sugar with a refreshing sweetness that dissolves in water and is about 60% stronger than sucrose. The sweetness is refined and refreshing, and it resembles the sweetness of fratatose rather than the discomfort associated with bitterness and astringency like saccharin. D-psicose is in harmony with other tastes of various substances such as acidity, salt to taste, astringency, umami, bitterness, etc., for sweetening and taste improvement of ordinary foods and beverages, quality improvement, etc. Can be advantageously used.

 Compositions targeted by the present invention (food, health food, patient food, food material, health food material, patient food material, food additive, health food additive, patient food additive, beverage, Health drinks, patient drinks, drinking water, health drinks, patient drinks, medicines, pharmaceutical ingredients, feeds, livestock and / or feeds for patients) are edible containing D-psicose and / or its derivatives And / or is any medicinal composition.

 A composition containing D-psicose as an active ingredient also serves as a food additive, food material, food and drink, pharmaceutical / quasi-drug, and feed power to suppress overweight and / or reduce overweight. The group power is also selected. Utilizing the functionality of the composition, it became possible to develop healthy foods and drinks, foods with nutritional foods and drinks for patients, and feed for domestic animals such as livestock, poultry and fish.

 That is, the food or drink is a functional food, a nutritional supplement, or a healthy food or drink for suppressing excessive increase in body weight and / or reducing overweight. The above feed is a feed for livestock, poultry and pets for suppressing excess weight gain and / or reducing overweight. Specifically, the food material of the composition containing the above-mentioned D-psicose as an active ingredient can be used in any form of food, beverage or feed.

In the case of using the above-mentioned functionality of the composition containing D-psicose of the present invention as an active ingredient, its content is not particularly limited, but it depends on the degree of intended function, usage mode, usage amount, etc. It can be adjusted as appropriate, for example 0.05 to 100% by mass. The composition for suppressing overweight and / or reducing overweight can be used for the human body, other foods and drinks, pharmaceuticals, feeds, and external preparations for skin. In addition, it can be taken by mouth or applied to the skin. Can be formulated into oral and parenteral products according to conventional methods, and used in various fields such as seasonings, food additives, food ingredients, food and drink, health food and drink, topical skin preparations, pharmaceuticals and feed be able to . For example, when blended in foods and drinks, foods and drinks can be provided for treating or preventing diseases that should suppress excess body weight gain and / or reduce overweight. From the prevention effect, it can be expected to be used as health food, nutritional food, etc. In addition, it can be used for livestock and feed or feed for Z or fish. By using it in the human body, other foods and drinks, pharmaceuticals, fertilizers, feeds, and external preparations for skin, it is possible to obtain an effect of treating or preventing an overweight and / or a disease that should reduce overweight. .

 [0022] In the yarn composition of the present invention, D-psicose and / or a derivative thereof is usually blended so as to be contained in an amount of 0.1 to 50% by weight in the composition. Preferably it is 1-50 weight%, More preferably, it is 10-30 weight%. However, if the content is low, it is sufficient to increase the intake of the composition. If the content is high, if the content is low, the intake of the composition may be reduced. Therefore, with regard to the blending ratio, it can be used at a blending ratio close to the lower limit for ordinary foods and beverages. When used in pharmaceuticals, tablets and capsules, it can be used at a blending ratio close to the upper limit. When humans take D-psicose and / or its derivatives, the dosage should be determined by the individual's age, weight and symptoms, etc., but in many cases the effective dose is D-psicose per adult It is appropriate to take 1-50g in divided doses before meals, after meals or with meals. The dose of D-psicose and Z or its derivatives is preferably taken as an oral dose of 0.3 to 50 g daily for adults as D-psicose, but may be increased or decreased appropriately depending on age and symptoms. Is possible. The daily anti-obesity and Z or ameliorating agent of the present invention should be taken once a day, or divided into 2 or 3 times a day at an appropriate interval, or before, after or after meals. Is preferred.

[0023] When the composition of the present invention is used for foods, it is in a form as it is, a form diluted with oil, a milk form meal, or a form to which a carrier generally used in the food industry is added. It may be prepared. The beverage form is a non-alcoholic beverage or an alcoholic beverage. Non-alcoholic beverages include, for example, non-carbonated beverages such as carbonated beverages, fruit juice beverages, and nectar beverages, soft drinks, sports beverages, tea, coffee, cocoa, etc. The form of food can be mentioned. Main departure Examples of the use of the light composition as a food material or food additive for the purpose of improving the above abnormalities of carbohydrate metabolism and / or lipid metabolism include powders or granules dissolved in tablets, capsules, beverages, etc. Solids, semi-solids such as jelly, liquids such as drinking water, and high-concentration solutions used after dilution. Furthermore, the composition of the present invention can be appropriately added to foods to provide health foods or sick foods for the purpose of obesity prevention and Z or improvement.

 As optional components, vitamins, carbohydrates, pigments, fragrances and the like that are usually added to foods can be appropriately blended. The food can be eaten in any form, liquid or solid. It can be eaten as a soft capsule encapsulated by gelatin or the like. Capsules are made, for example, with a gelatin film prepared by adding water to raw gelatin and dissolving it, and then adding a plasticizer (such as glycerin or D-sorbitol).

[0024] The food material and food additive of the present invention will be described. Since D-psicose is soluble in water, it can be easily added to beverages such as coffee and juice, confectionery, and various processed foods. Furthermore, the composition of the present invention can be appropriately added to foods and / or food materials to obtain processed foods for health and / or patients for the purpose of preventing obesity and / or improving obesity. . The composition of the present invention is used as a food material and / or a food additive for preparing food that can be eaten, taken or taken by a person and animals who need obesity prevention and / or improvement of obesity with a general meal. It can be used to prevent excessive weight gain, improve overweight, increase QOL, reinforce the effects of drugs or other foods used for similar purposes, and reduce the amount used. Can be reduced.

 [0025] When D-psicose and / or its derivatives are ingested by humans, the dosage should be determined by the individual's age, weight and symptoms, etc. In many cases, effective doses are rare sugars per day. It is appropriate to take -50g in divided doses before meals, after meals or with meals.

[0026] The use form of the composition of the present invention as a food material or food additive for the purpose of preventing obesity and / or ameliorating obesity, etc. includes powders dissolved in tablets, capsules, beverages, etc. Solid agents such as granules, semi-solid bodies such as jelly, drinking water, etc. Liquid, high-concentration solution to be used after dilution. Furthermore, the composition of the present invention can be appropriately added to foods to provide health foods or sick foods for the purpose of preventing obesity and / or improving obesity.

 [0027] The drinking water of the present invention will be described. Obesity also presents an unbalanced calorie intake and calorie consumption, which is difficult to treat because the cause is deeply rooted in lifestyle. Currently, no anti-obesity drugs such as anorexic drugs have been approved in Japan, and lifestyle modifications and exercises such as dietary restrictions are being carried out as methods for treating obesity. However, dietary restrictions and exercise are a great stress for people who are obese. In addition, even if you are not overweight, you may have dietary restrictions to lose weight, and if you lose your nutritional balance and worsen your physical condition, you will also be in a habit!

 [0028] The drinking water of the present invention is a colorless and transparent, odorless, almost tasteless aqueous solution containing 1 to 5% by weight of D-psicose and / or a derivative thereof. The amount is preferably 1.5 to 4% by weight, more preferably 2 to 3% by weight. If it is less than 1% by weight, the effect of preventing obesity and / or improving the condition of obesity is not sufficient. If it exceeds 5% by weight, the sweetness derived from D-psicose, which has 60% sweetness of sugar, can be felt. This drinking water is colorless and transparent, and has a strong sweetness that smells. Therefore, it can be used as drinking water as it is, and can also be used for cooking rice, cooking, tea and coffee. By using the drinking water of the present invention to make daily meals and luxury goods in this way, dietary restrictions can be relaxed and body weight can be controlled without particular awareness. In addition, it is presumed that the body weight within the normal range is not affected from the research results on which the present invention is based, so that it is considered that the body weight can be adjusted more safely. This will help improve the quality of life for those who are overweight or overweight.

 [0029] The agent of the present invention will be described. The present inventor examined in detail the effect of D-psicose on the body weight of rats using genetic and experimental obesity model animals. As a result, we found that D-psicose has the effect of suppressing weight gain and reducing overweight.

[0030] Drugs containing D-psicose and / or its derivatives as an active ingredient for the purpose of preventing obesity and / or improving obesity status are used alone or in general. Formulated with appropriate additives such as form, stabilizer, preservative, binder, disintegrant, liquid, granule, fine granule, powder, tablet, capsule, pill, ointment, patch, spray An appropriate dosage form such as an agent, spray or injection can be selected and formulated and administered orally, nasally, transdermally or intravenously.

 [0031] When the composition of the present invention is applied clinically as a drug, D-psicose and / or a derivative thereof as an active ingredient is used as a solid, semi-solid or liquid pharmaceutical carrier such as a diluent, an excipient. It is desirable to prepare a preparation containing additives such as an agent and a stabilizer. The ratio of the active ingredient to the carrier component can vary between 1 and 90% by weight. The dosage form and mode of administration are liquids, granules, fine granules, powders, tablets, capsules, pills, ointments, patches, sprays, sprays or injections. Or it may be administered orally with the bulk. When used as a liquid, it may be administered nasally or intravenously in addition to oral administration.

 [0032] A pharmaceutical organic or organic solid, semi-solid or liquid carrier, solubilizer or diluent suitable for oral administration, nasal administration, transdermal administration or intravenous administration is used as a composition of the present invention. It can be used to prepare as a medicine. Water, gelatin, lactose, starch, magnesium stearate, talc, animal and vegetable oil benzyl alcohol, gum, polyalkylene glycol, petroleum oil, coconut oil, lanolin, or other carriers used in medicine All can be used as a carrier for a drug containing the composition of the present invention. In addition, stabilizers, moistening agents, emulsifiers, and salts for adjusting the osmotic pressure and maintaining the pH of the compounding agent can be appropriately used as auxiliary agents.

 [0033] Furthermore, the drug containing the composition of the present invention contains other pharmaceutically effective ingredients that can be appropriately administered together with the drug of the present invention in obesity prevention and / or improvement of obesity status. May be. In the case of granules, fine granules, capsules, powders, tablets, ointments, patches, sprays or sprays, it is preferable to contain 5 to 80% by weight of the composition of the present invention. In the case of solution or injection, the corresponding amount (ratio) is preferably 1 to 80% by weight.

[0034] When administered orally, the clinical dose is preferably taken as an oral dose of 1 to 50 g daily for adults as D-psicose and / or its derivatives, but may be increased as appropriate depending on age, symptoms, etc. It can also be reduced. The daily dose of the agent of the present invention is preferably administered once a day or divided into two or more times at an appropriate interval, or before, after or with a meal.

 [0035] The preparation raw material of the present invention will be described. When manufacturing other drugs that are expected to prevent obesity and / or improve obesity as a drug, D-psicose and / or its derivative is used as a drug substance as a general excipient, stabilizer, preservative, It can also be used for purposes such as binders and disintegrants. Alternatively, for example, when obesity appears secondary, it is necessary to improve the obesity state in addition to the treatment of the causative disease. The product can also be used as a raw material for preparation as described above. In this case, the amount of D-psicose and / or its derivative used and the ratio with other drugs can be appropriately adjusted depending on the content or nature of these therapeutic agents in the preparation.

 [0036] [Action]

 In genetically obese rats, continuous oral administration of D-psicose suppressed rat weight gain. In addition, when D-psicose was orally administered to experimental obese rats, the increased body weight decreased.

[0037] The present invention will be described in more detail by way of examples and test examples, but the present invention is not limited by these! /.

 Example

 [0038] Type of bait used in the experiment: mouse “rat” hamster CE2 manufactured by Claire Japan

 Feeding method: free intake

 Food intake: D-psicose aqueous solution administration group and control group showed no difference. (Observations during the experiment showed no significant changes in animal behavior.)

[0039] [Method of experiment]

 1. Experiments using genetically obese rats

Ten-week-old male Zucker (fa / fa) rats (hereinafter referred to as Zuc (fa)) were used. These animals were administered in distilled water (control group), D-psicose 0.5 g / kg (P0.5), D-psicose lg / kg (Pl), D-psicose 2 g / kg. Group (P2), D-psicose 4g / kg group (P4), 5 groups Divided into. D-psicose was dissolved in distilled water and the administration volume was 10 mL / kg.

 The above D-psicose solution or distilled water was orally administered by gavage once a day. Body weight was measured at 3 or 4 day intervals. The measured values were expressed as mean values and standard errors, and were performed using a significant difference test or a Tukey multiple range test.

 2. Experiments using experimental obese mice

 4-week-old ddY mice were used. Aurothioglucose (A TG) for experimental obesity

 500 mg / kg was administered intraperitoneally. On the 15th day of administration, 7 mice died out of 60 mice administered ATG, and 53 mice survived. Among surviving mice, animals with a body weight greater than the mean value of the animals (non-ATG control group) that had not been administered ATG (non-ATG control group) + standard deviation X2 were regarded as experimentally fertile mice. Of the 53 surviving mice, 26 were experimental obese mice.

 Experimental obese mice are divided into 3 groups: distilled water administration group (ATG control group), D-psicose 1% aqueous solution administration group (ATG + P1%) and D-psicose 10% aqueous solution administration group (ATG + P10%). It was. These D-psicose aqueous solution administration groups were given D-psicose aqueous solution from the 15th day to the 28th day of ATG administration and distilled water after the body weight measurement on the 18th day as drinking water.

 Body weight was measured at 3 or 4 day intervals. The measured values are expressed as average values and standard errors. ¾, g, Test iiTukey multiple range test is used.

[Experimental result]

 1. Experiments using genetically obese rats

 The average body weight of Zuc (fa) at the start of the experiment was 405.6 ± 3.0 g (N = 100). The body weight of Zuc (fa) in the control group increased from 4 to 6 g per day, and reached 504.4 ± 4.1 g (N = 20) on the 21st day after the start of the experiment. The weight gain of animals in the D-psicose administration group was less than that in the control group. The body weight in the P4 group was significantly different from the control group at all measurement points after the 10th day of D-psicose administration. The P2 group showed significantly less body weight than the control group on day 21 after D-psicose administration (Fig. 1).

 2. Experiments using experimental obese mice

The average body weight of animals in the non-ATG control group on the 15th day after ATG administration is 36.0 ± 0.8 g (N = 10) g. I got it. On the other hand, the average body weight of experimental obese mice was 39.2 ± 0.3 g (N = 5) g.

 In experimental obese mice, when D-psicose was administered with little strength (ATG control group), the body weight continued to increase, and on day 42 after ATG administration, it became 53.3 ± 3.7 g (N = 5) g. In the D-psicose group, the body weight of the animals in the ATG + P1% group increased almost the same as in the ATG control group, reaching 55.6 ± 3.5 g (N = 5) g on the 42nd day after ATG administration. The body weight of animals in the ATG control group and ATG + P1% group was significantly greater than the body weight of animals in the non-ATG control group at all time points. The body weight of the animals in the ATG + P10% group decreased immediately after administration of D-psicose, and during the period of administration of D-psicose (from day 15 to day 28 of ATG administration), the body weight of the animals in the non-ATG control group There was no significant difference. Even after changing the drinking water from D-psicose 10% aqueous solution to distilled water on the 28th day of ATG administration, the body weight of the animals in the ATG + P10% group remained decreased, and the body weight of the animals in the non-ATG control group There was no significant difference between the two (Figure 2).

[0041] [Discussion]

 In experiments using genetically obese rats, when gavage administration of D-psicose of 0.5 g / kg or more tended to show a smaller weight gain compared to the control group, the group receiving 4 g / kg There was a significant difference from the control group. In the group administered D-psicose 4g / kg, the difference was also evident on the 10th day after starting administration.

 On the other hand, in an experiment using experimental obese mice, the body weight decreased to about the same weight as normal mice immediately after using 10% D-psicose aqueous solution as drinking water. The weight loss when D-psicose 10% aqueous solution was used as drinking water remained even after the drinking water was changed to distilled water. Moreover, the body weight was reduced by the D-psicose 10% aqueous solution. The body weight was not significantly lower than that of normal mice.

 In this study, the effect of D-psicose on the suppression of body weight gain in diseased animals and the decrease in increased body weight was found to be rare for obesity caused by abnormal sugar metabolism or lipid metabolism in humans. This indicates that there is a high possibility that sugar will show an improvement effect.

 Industrial applicability

[0042] According to the present invention, it is clear for the first time that D-psicose and / or a derivative thereof has the effect of suppressing weight gain and reducing the weight gain in obese animals. I got it. This is a result of presuming that D-psicose and / or its derivatives show an effect of preventing obesity and / or improving obesity in humans, and provides a new means for preventing and dealing with obesity. is there.

Claims

The scope of the claims  [1] A composition comprising D-psicose, which suppresses overweight and / or reduces overweight. [2] A composition comprising D-psicose, characterized by preventing obesity and improving Z or obesity status. [3] The composition according to claim 1 or 2, which is formulated so as to contain D-psicoseca ^ to 90% by weight.  [4] The composition of claim 1, 2 or 3, wherein D-psicose is D-psicose and Z or a derivative thereof.  [5] Use of the composition of claim 1, 3 or 4 for persons and Z or animals in need of inhibition of overweight and / or reduction of overweight. A method of reducing excess weight and / or reducing excess weight. [6] Prevention and prevention of obesity characterized by the use of the thread and adult of claim 2, 3 or 4 for persons and Z or animals in need of prevention of obesity and improvement of Z or obesity status Or a method to improve obesity.